These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38343119)

  • 21. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
    Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
    Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
    Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
    Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emicizumab for acquired haemophilia A: A case series.
    Engelen MM; Vandesande J; De Bent J; Van Laer C; Labarque V; Jacquemin M; Peerlinck K; Hermans C; Verhamme P; Vanassche T
    Haemophilia; 2023 Jul; 29(4):1049-1055. PubMed ID: 37276345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired haemophilia and haemostatic control with recombinant porcine factor VIII: case series.
    Campbell S; Mason J; Prasad R; Ambrose H; Hunt S; Tran H
    Intern Med J; 2021 Feb; 51(2):215-219. PubMed ID: 32043744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
    Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
    Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.
    Tarantino MD; Cuker A; Hardesty B; Roberts JC; Sholzberg M
    Haemophilia; 2017 Jan; 23(1):25-32. PubMed ID: 27511890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
    Nardi MA
    Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
    Grandoni J; Duretz V; Bonzo D; Evans S; Plantier JL
    Haemophilia; 2021 Mar; 27(2):321-328. PubMed ID: 33550714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
    Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
    J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
    Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.
    Hamedani NS; Oldenburg J; Pötzsch B; Müller J
    PLoS One; 2022; 17(7):e0271330. PubMed ID: 35834493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.
    Kershaw G; Dix C; Chen VM; Cai N; Khoo TL
    Pathology; 2022 Oct; 54(6):755-762. PubMed ID: 35577608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
    Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.